Managing Synthetic Cannabinoid Toxicity and Withdrawal: What Clinicians Know So Far | Research

The takeaway

A review found that daily synthetic cannabinoid use produces dependence and withdrawal that is poorly characterized, with limited evidence suggesting benzodiazepines and quetiapine may provide some symptom relief.

Clinicians managing synthetic cannabinoid users and anyone interested in SC addiction.

No established evidence-based treatment exists for synthetic cannabinoid withdrawal

What the researchers found

This review addressed both acute toxicity and the less-discussed problem of dependence and withdrawal from synthetic cannabinoids (SCs).

While case reports and media coverage focus on severe acute toxicity, the review highlighted that daily SC use resulting in dependence and withdrawal is a significant and often overlooked concern. Data collected from cannabis smokers in New York City over 3.5 years (2012-2015) confirmed a subset of people who use SCs daily.

There is no established evidence-based treatment for SC withdrawal. Some symptom relief has been reported with benzodiazepines and the atypical antipsychotic quetiapine, but controlled studies are lacking. The review called urgently for empirical studies on SC acute effects, withdrawal characterization, and treatment strategies.

Why it matters

As synthetic cannabinoids continue to circulate, clinicians need guidance on managing not just acute crises but also the dependence and withdrawal that develop with regular use. The current lack of evidence-based treatment protocols leaves clinicians without clear direction.

The numbers in context

3.5 years of survey data (2012-2015) from the NYC metropolitan area. Benzodiazepines and quetiapine showed some withdrawal symptom relief. No controlled treatment studies existed at the time.

How the study worked

Literature review combined with original survey data on SC use demographics, frequency, and adverse effects from the New York City metropolitan area (2012-2015).

What this study cannot tell us

The review acknowledged a lack of controlled studies on SC effects and treatment. Survey data from NYC may not represent other regions. The rapidly changing SC market means findings about specific compounds may become outdated quickly.

How to read the evidence

This review combines published literature with original survey data but notes the near-complete absence of controlled treatment studies.

When this study was published

Published in 2016. Some additional clinical experience with SC withdrawal has accumulated since then.

The bigger picture

While much attention focuses on the dramatic acute toxicity of synthetic cannabinoids, the chronic use and dependence aspect may affect more people over time. The review highlighted a gap in addiction medicine: extensive treatment literature exists for most substances of abuse, but almost nothing for synthetic cannabinoids.

Questions still open

What is the typical timeline and severity of SC withdrawal? Would treatments effective for cannabis withdrawal also work for SC withdrawal?

Common questions

Is synthetic cannabinoid withdrawal dangerous?

SC withdrawal can be significant and distressing, though it has not been as systematically characterized as withdrawal from other substances. Symptoms may include anxiety, insomnia, irritability, and in some cases more severe neurological effects. The lack of controlled studies means the full risk profile is not well understood.

Why is SC dependence harder to treat than cannabis dependence?

SCs are full agonists at CB1 receptors (more potent than THC), the compounds vary unpredictably between batches, and there are no standardized treatment protocols. Additionally, SC users often have more complex substance use patterns and psychiatric comorbidities.

Read the original research

Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal.

Current psychiatry reports, 18(5), 52

View on PubMed ↗Publisher’s paper ↗

Citation

Cooper, Ziva D. (2016). Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal.. Current psychiatry reports, 18(5), 52. https://doi.org/10.1007/s11920-016-0694-1